GO
| HSI1 | 24,142.20 | +645.31 | 213.13B |
| HSCEI1 | 8,047.14 | +276.88 | 69.68B |
| Back Zoom + Zoom - Block Traded | |
|
SBP GROUP Grants Exclusive License for TQC3721 to AstraZeneca, Involving Up to USD1.9B
2026-07-08 08:47:32 SBP GROUP (01177.HK) announced that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of the Company, entered into an exclusive license agreement with AstraZeneca (AZN.US) for the development, manufacturing and commercialization of the Group’s PDE3/4 inhibitor, TQC3721. The Group is eligible to receive an upfront payment of USD200 million, with additional development, regulatory and sales milestones, totaling up to USD1.9 billion, as well as tiered royalties ranging up to double-digit percentages based on the annual net sales of TQC3721 products. Pursuant to the Agreement, the Group shall grant AstraZeneca an exclusive license to develop, manufacture and commercialize TQC3721 outside China. AstraZeneca also gains exclusive global rights for certain future development programmes. ~ AASTOCKS Financial News Website: www.aastocks.com | |